Genmab

Ofatumumab i nyt fase 3 http://clinicaltrials.gov/ct2/show/NCT01659021?term=ofatumumab&rank=44

golfhouse du er en krævende kunde Vi biotekfester lige

(tom indlæg)

Tak. Så er zealand updated

I1989 har du set SPG har købt helt op i et datter selskab og nu også udvider aktietilbagekøbet

Ja det tror jeg RTH

Inden kalenderen går i 2013-Har Vestas fået de ordre i hus som de lovet-Anderledes kan det ikke være.:-)

Jeg er ikke sikker på elevatoren går helt op til øverste etage på sælgeren her

Enig sukker mht. det sidste. Det er vigtigt de kan holde et fornuftigt flow af milestone og nye aftaler.

Der var altid være problemer undervejs og dem kommer vi nok ikke til at høre meget om, så hvis der pludselig går lige lovlig langt mellem milestones og evt. nye partneraftaler, så er der måske kommet problemer af større karat !

Er det stadig MLI der sælger.

skræmme blokken er tilbage i 71,6. 55000 styk

Aka det er til højre benet kom nu tøssedreng

Jeg tror der venter mig en røvfuld ud over der sædvanlige.

14 dage gammel artikel, men dog interessant for Genmab: http://www.bloomberg.com/news/2012-05-23/glaxo-avoids-market-for-lemons-by-acquiring-its-collaborators.html

http://www.fda.gov/Drugs/DrugSafety/ucm250575.htm

Celgene, the company that markets Revlimid in the United States and inter­nationally, announced this morning that it has withdrawn its applica­tion in Europe to have the drug approved for use as initial therapy for newly diagnosed myeloma patients as well as for maintenance therapy. The company also is postponing until next year a similar application it had intended to file in 2012 with the U.S. Food and Drug Administration (FDA). The European application was withdrawn due to concerns raised by regulators about the link between Revlimid (lenalidomide) and second cancers (also known as second primary malignancies). Celgene’s announcement came as a surprise to many observers — so much so that Celgene’s stock declined more than 11 percent today.

Although the results were early, Rafael Fonseca, MD, professor of medicine at the Mayo Clinic in Scottsdale, Ariz. told MedPage Today he was impressed. "The daratumumab data were the most exciting information presented at that session. The responses we saw in reduction of M-protein were impressive. I don't think you can get those kinds of reductions just with steroids. There was a dose response to the treatment as well. This drug has a lot of promise."

http://www.forbes.com/sites/matthewherper/2012/06/21/blood-cancer-shockers-celgene-dives-while-onyxx-soars/?partner=yahootix .... interessant for Genmab. Revlimid har problemer og carfilzomib er næsten sikker på approval i MM - blockbuster potentiale. Så må Daratumumab have tilsvarende potentiale Revlimid er i fare for at blive banded efter min mening jf. tidligere indlæg omkring væsentlig risiko ved brugen i form af stærkt forøget cancerrisiko.

Daratumumab in Combination With Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma This study is not yet open for participant recruitment. Verified June 2012 by Genmab